Actinium Faces Derivative Suit Over FDA Application Claims

By Emilie Ruscoe · May 14, 2025, 11:24 PM EDT

Officers and directors of biopharmaceutical company Actinium Pharmaceuticals Inc. face a shareholder derivative action accusing them of breaching their fiduciary duties after the company's lead product candidate failed to secure a...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login